Tesamorelin + Ipamorelin 10mg Blend

Tesamorelin + Ipamorelin — Research Overview

Introduction

Tesamorelin + Ipamorelin is a dual-peptide research blend combining a stabilized growth hormone–releasing hormone
(GHRH) analog with a selective growth hormone secretagogue (GHS). This combination is studied for its potential to
support endogenous pulsatile growth hormone (GH) release through complementary receptor pathways.

Tesamorelin acts primarily through the GHRH receptor in the anterior pituitary, while Ipamorelin selectively targets
the ghrelin/growth hormone secretagogue receptor, known as GHS-R1a. Together, these pathways are researched for their
role in GH signaling, IGF-1 activity, body composition, visceral fat metabolism, and muscle tissue research.

Overview

Tesamorelin is a modified 44-amino acid GHRH analog designed to improve peptide stability and resistance to enzymatic
degradation. It stimulates pituitary release of endogenous GH, which can lead to downstream increases in insulin-like
growth factor-1, or IGF-1.

Ipamorelin is a selective pentapeptide growth hormone secretagogue that mimics ghrelin signaling at the GHS-R1a receptor.
Unlike several earlier GHRPs, Ipamorelin has been studied for its ability to stimulate GH release without substantial
elevation of cortisol, prolactin, or ACTH.

Because Tesamorelin and Ipamorelin act through different but complementary signaling pathways, this blend is frequently
studied for enhanced GH pulsatility and extended secretory response.

Chemical Characteristics

Molecular Structures

Tesamorelin Molecular Structure

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂

Tesamorelin is modified with a trans-3-hexenoic acid group, which is studied for improving stability and resistance to enzymatic breakdown.

Ipamorelin Molecular Structure

Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Aib refers to α-aminoisobutyric acid, while D-2-Nal refers to D-2-naphthylalanine.

Research Applications

Growth Hormone Pulsatility

Tesamorelin stimulates GH release through the GHRH receptor pathway, while Ipamorelin activates GHS-R1a receptors.
Research suggests that simultaneous activation of both pathways may produce amplified pulsatile GH secretion compared
to either pathway alone.

IGF-1 Signaling

Both Tesamorelin and Ipamorelin are studied for their influence on circulating IGF-1 through endogenous GH stimulation.
IGF-1 signaling is frequently evaluated in relation to muscle metabolism, tissue turnover, recovery signaling, and
body composition research.

Visceral Fat and Metabolic Research

Tesamorelin has been studied extensively in visceral adiposity and lipodystrophy models, particularly involving abdominal
fat reduction and lipid metabolism. Clinical research has evaluated Tesamorelin for changes in visceral adipose tissue,
hepatic fat fraction, triglycerides, and cholesterol markers.

Muscle Composition and Recovery

Growth hormone secretagogues and GHRH analogs have been investigated for their potential influence on lean tissue
maintenance, muscle density, and recovery-related signaling. Imaging studies involving Tesamorelin have evaluated changes
in intramuscular fat and muscle density markers.

Selective Secretagogue Activity

Ipamorelin remains notable among GHRPs due to its selectivity. Human and animal studies have shown GH-releasing activity
with minimal influence on ACTH, prolactin, or cortisol when compared with several earlier growth hormone secretagogues.

Research Summary

Tesamorelin + Ipamorelin combines two distinct GH-modulating peptide classes into a single research formulation.
Tesamorelin functions as a stabilized GHRH analog, while Ipamorelin functions as a selective ghrelin receptor agonist.

Together, these compounds are studied for their effects on endogenous GH pulsatility, IGF-1 signaling, visceral fat
metabolism, body composition, muscle density, and recovery-related pathways.

Other Known Titles

• Tesa + Ipa
• Tesamorelin / Ipamorelin Blend
• GHRH + GHS Combination
• Selective GH Secretagogue Blend

Tesamorelin + Ipamorelin References

Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Andersen, P. H., Nielsen, P. F., Thim, L., Kristensen, P.
Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561.

Raun, K., Johansen, N. L., Thøgersen, H., Hansen, B. S., Thim, L., Madsen, K.
Ipamorelin, a new growth hormone releasing peptide with selectivity for the growth hormone secretagogue receptor.
Growth Hormone & IGF Research. 1999;9(1):10–17.

Ghigo, E., Arvat, E., Gianotti, L., Imbimbo, B. P., Lenaerts, V., Thorner, M. O., Camanni, F.
Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445–460.

Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., Grinspoon, S.
Effects of tesamorelin in HIV-infected patients with excess abdominal fat.
Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291–4304.

Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C.,
Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E.,
Hadigan, C. M., Grinspoon, S. K. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV.
The Lancet HIV. 2019;6(12):e821–e830.

Clemmons, D. R., Miller, S., Mamputu, J. C. Safety and metabolic effects of tesamorelin, a growth hormone-releasing
factor analogue, in patients with type 2 diabetes. PLoS ONE. 2017;12(6):e0179538.

Notice of Compliance

The mission of BioGenix Peptides™ is to provide researchers with the highest-quality, Ultra-Pure Series™ compounds to
help unlock the full potential of this evolving field. With precision, purity, and scientific integrity at the core of
our operations, BioGenix Peptides™ is dedicated to supporting responsible exploration and discovery.

Products from BioGenix Peptides™ are not intended for human consumption. They are supplied exclusively for in-vitro and
pre-clinical research purposes.

By purchasing or using these products, the Customer accepts full responsibility for their handling and use, and agrees
to indemnify and hold BioGenix Peptides™ harmless from any claims resulting from misuse.